WO1984001289A1 - Purified and antigenically selective vaccines for domestic animals - Google Patents
Purified and antigenically selective vaccines for domestic animals Download PDFInfo
- Publication number
- WO1984001289A1 WO1984001289A1 PCT/US1983/001456 US8301456W WO8401289A1 WO 1984001289 A1 WO1984001289 A1 WO 1984001289A1 US 8301456 W US8301456 W US 8301456W WO 8401289 A1 WO8401289 A1 WO 8401289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- immunizing agent
- vaccines
- vaccine
- protein
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 66
- 241001465754 Metazoa Species 0.000 title claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 33
- 229940124452 immunizing agent Drugs 0.000 claims abstract description 20
- 230000003612 virological effect Effects 0.000 claims abstract description 12
- 239000011859 microparticle Substances 0.000 claims abstract description 11
- 238000009739 binding Methods 0.000 claims abstract description 10
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 230000000536 complexating effect Effects 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims description 25
- 230000000890 antigenic effect Effects 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 7
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 208000031295 Animal disease Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 abstract description 9
- 230000001580 bacterial effect Effects 0.000 abstract description 8
- 229940031626 subunit vaccine Drugs 0.000 abstract description 4
- 238000002649 immunization Methods 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 42
- 108091007433 antigens Proteins 0.000 description 42
- 102000036639 antigens Human genes 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 14
- 239000002523 lectin Substances 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 108090001090 Lectins Proteins 0.000 description 8
- 102000004856 Lectins Human genes 0.000 description 8
- 241000282887 Suidae Species 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 241000589562 Brucella Species 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000009305 pseudorabies Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229960004854 viral vaccine Drugs 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 241000219739 Lens Species 0.000 description 3
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MJQHZNBUODTQTK-WKGBVCLCSA-N (2s,3r,4s,5r,6r)-2-[[(1s,3s,4s,5s,8r)-3-[(2s,3r,4s,5s,6r)-2-[[(1s,3r,4s,5s,8r)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5- Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H]2OC[C@@H]1O[C@@H](O[C@@H]1[C@H]([C@H](O[C@H]3[C@H]4OC[C@@H]3O[C@@H](O)[C@H]4O)O[C@H](CO)[C@@H]1O)O)[C@H]2O MJQHZNBUODTQTK-WKGBVCLCSA-N 0.000 description 2
- 241000223836 Babesia Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000223838 Babesia bovis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the field of this invention is animal vaccines prepared from aqueous microorganism cultures.
- the desired immunizing agent which has been propagated by a culture procedure may be a virus, a bacteria, or other microorganism such as a protozoa.
- the method is highly advantageous for preparing vaccines from soluble protein or glycoprotein antigens derived from virus or bacteria.
- the objectives of this invention involve the recovery of the selected immunizing agent in purified form, and its incorporation in a parenteral vaccine of effective immunogenicity. More specifically, it is an objective to provide a method in which the specific immunizing agent can be recovered and incorporated in substantially pure form in a vaccine while at the same time reducing the required number of preparatoy steps, and thereby reducing the cost of the preparation of the vaccine.
- These objectives are particularly important with respect to subunit viral and bacterial vaccines of practical and commercial use of which has been limited by the high cost of preparation.
- the cells can be readily separated from the culture media suspensions by centrifigation, and after separation, they can be washed to remove soluble residues. Solubilized bacterial antigens, viruses, andsubunit viral proteins are much more difficult to prepare as purified concentrates.
- Viruses for vaccine use are produced in cell-containing media, adapted tissue cells or other cells serving as the host for the propagation of the virus.
- the cells can be lysed to liberate the virus, but it is difficult to efficiently separate the viral particles for the other solids of the media residues. Such separation is even more difficult where the viral protein has been solubilized, such as by the action of a nonionic detergent, the antigenic proteins being in solution together with other soluble substances. Similar problems are encountered when antigenic components of bacteria are solublized, or where the desired antigen is produced in soluble form by a genetic engineering procedure, such as the culturing of cells containing plasmids providing genetic units producing the desired antigenic protein.
- IgG antibodies that bind selectively to specific antigenic protein can be prepared and used for the separation of the antigenic protein.
- Protein A has been used as a surface-component of the micro-particles to be employed for the separation.
- Protein A may be coupled to beads of a chromatographic adsorbent such as cross-linked agarose gel beads.
- the Protein A binds with the Fc regions of the specific antibodies, leaving the Fab arms free for binding with the antigenic protein.
- the antigenic protein is recovered by breaking the complex, such as by the use of a suitable eluting agent in column adsorption procedures.
- the antigen-antibody- Protein A-carrier particle complex can be directly used as a vaccine.
- the method and vaccines of this invention are based in part on the discovery that after adsorption of the antigen further processing is not necessary, and that vaccines providing effective immunization can be directly prepared from the adsorption complex. This is surprising since the immunizing activity of the antigenic protein would have been thought to have been interfered with by the antibody binding.
- the method of this invention and the vaccines produced thereby can be applied with particular advantage to the preparation of subunit viral vaccines.
- This invention provides an efficient way of preparing such vaccines on a commercial basis. This is important because subunit viral vaccines can be used in conjunction with programs for eradication of bacterial and viral diseases.
- the immunity produced by a subunit vaccine can be distinguished from the immunity of natural infection because a larger complement of antibodies will be present after natural infection.
- the antibody-binding micro-particles used in preparing vaccines according to the present invention may comprise killed bacterial cells having a protein substance in their cell walls capable of selective binding to the Fc regions of the antibodies.
- it may be the substance known as Protein A
- the cells providing Protein A in the cells walls may be Staphylococcus aureus.
- Preserved (e.g. formalinized) cells of S. aureus (Cowan 1 Strain) are available from Calbiochem-Behring Corp., San Diego, California; or from Bethesda Research Laboratories, Inc., Gaithersburg, Maryland.
- other killed bacterial cells can be used which have a cell wall protein binding to the Fc regions of the antibodies.
- the protein A or other Fc-binding bacterial protein may be immobilized on synthetically prepared micro-particles or microspheres, such as the chromatographic gel beads used in chromatography adsorption columns. Protein A or similar protein may be chemically coupled to the substance forming the microspheres.
- a commercial product of this kind is available from Pharmacia Fine Chemicals, a division of Pharmacia, Inc., Piscataway, New Jersey, being sold as Protein A-Sepharose CL-4B, which comprises Protein-A covalently coupled to the cross-linked agarose gel beads.
- microspheres providing Protein A in their outer surfaces can be prepared by mixing the Protein A with aqueous albumin and forming the mixture into microspheres by the hot oil method described in United States Patent 4,230,685, or as described in Scheffel, et al, J. Nuclear Med. , Vol. 13, No. 7, 498-503 (1972).
- Patent 4,230,685 the procedure, of Patent 4,230,685 is followed, the magnetic particles will be omitted from the microspheres, the resulting procedure being similar to that described by the cited Scheffel, et al reference.
- the antibody preparations useful in the present invention are those which contain one or more specific antibodies having Fb regions reacting with Protein A or similar protein on the surfaces of the micro-particles.
- Protein A is able to interact with a wide variety of IgG molecules from various species.
- the antibodies may be prepared in the same species of animals from which the vaccine is to be used, such as cattle, sheep, or swine.
- a hyperimmune serum can be prepared according to known procedures. See, for example Methods in Immunology and Immunochemistry, I, 209-224 (1967, Academic Press).
- the antibodies can be prepared in another host animal.
- rabbits can be used since the rabbit immunoglobulins binding to Protein A include all subclasses of IgG.
- mouse monoclonal antibodies specific for the desired antigen can be employed.
- the antibodies can be readily removed from dilute solutions thereof, such as animal sera, by contacting the solutions with the micro-particles. This contacting reaction can be carried out in a column or on a batch basis.
- the resulting separated complex of the antibody-Protein A-carrier particle is then used to prepare the vaccine, and is hereinafter referred to as the separator complex.
- the immunizing agent is prepared by in vitro microorganism culture.
- Virus may be propagated in cell culture in an aqueous medium, and the virus liberated by rupturing (lysing) cells, such as by sonication. Viral particles are liberated into the aqueous medium, and the residue solids of the cell mass can be separated by centrifigation, leaving the viral particles in the aqueous medium, which will also contain other components such as unwanted antigenic protein and other culture residue substances.
- the virus may be dissolved by addition of a solubilizing agent, such as nonionic detergent, or a proteolytic enzyme.
- Antigens may also be extracted from the membranes of virus infected cells with non-ionic detergents.
- the antibodies immobilized on the micro-particles will be specific to the desired immunizing agent, such as antibodies which bind to the whole virus, or antibodies which bind to selected antigenic protein constituents of the solubilized virus or extracted antigens.
- the antigens may be envelope glycoproteins or one or more specific glycoproteins or other protein constituents of the virus.
- the method of this invention can also be applied to the preparation of vaccines from specific antigens produced by genetic engineering procedures.
- the plasmid-containing cells are propagated in aqueous medium to produce the antigen, which may have been at least partly liberated into the aqueous media.
- the cells will be lysed to further liberate the soluble antigen, and the cell mass removed to provide an aqueous solution of the antigen which will also contain unwanted antigenic protein and other culture residue substances. This solution is then processed in the same manner as described above for subunit viral protein.
- the method of this invention may be used for the recovery of protozoan parasites such as Babesia species which occur in red blood cells.
- protozoan parasites such as Babesia species which occur in red blood cells.
- These agents can be produced in large quantities by infecting splenectomized animals or by in vitro propagation. Red blood cells containing the agents are first lysed releasing the protozoan. The liberated protozoans and those protozoans that occur extracellularly are then aggregated by specific antibodies adsorbed to protein A immobilized on microparticles or to protein A contained on the surface of Staphylococcus aureus. The aggregated antigen-antibody complexes are separated from the particulate and soluble remnants of red blood cells by differential centrifugation and washing.
- the reaction of the immunizing agent in the aqueous admixture with the separator complex may be carried out on a batch basis or in a column.
- the antigenic protein in solution will bind to the separator complex so that the resulting antigenic complex can be readily separated from the residual solution by standard separating procedures such as centrifigation.
- the reaction is carried out in a column, the antigen will be held up by selective adsorption on the separator complex, while a residual solution will pass through and out of the column.
- the column material containing the adsorbed antigen can then be removed from the column, after washing, if desired, and used to prepare the vaccine in the same manner as the separated precipitate from the batch reaction.
- a sufficient amount of the separator complex is present to react with all of the antigenic protein. If desired, excess separator complex can be present, and such excess separator complex may be separated with the antigenic protein complex, and may remain in the preparation for vaccine use. Preferably, however, any such excess is kept to a minimum to reduce costs in preparing the vaccine.
- the complexed immunizing agent is prepared in vaccine dose form for administration to the domestic animal.
- the particulate antigenic complex may be suspended in an injectable liquid carrier, such as a sterile phosphate-buffered saline solution, as used for parenteral injections.
- an injectable liquid carrier such as a sterile phosphate-buffered saline solution
- standard adjuvant compositions can be combined with the complexed immunizing agent to enhance the immunogenic response.
- an aluminum hydroxide adjuvant can be employed, or an oil-type adjuvant such as vegetable oil adjuvant, Freund's Incomplete Adjuvant, etc.
- the method of this invention and the vaccines which can be produced thereby are further illustrated by the following examples.
- a subunit vaccine for immunizing pigs against Pseudorabies was prepared as follows:
- Pseudorabies virus was progated by cultivation of the virus in a pig kidney cell line. The virus infected cells are harvested when 100% of the cell monolayer shows ⁇ ytopathic effect.
- the cells are washed and then extracted with a
- Triton-X-100 prepared in Tris/Tricine buffer .025 M pH 8.6.
- the detergent solution is added at the rate of 1 ml per 1 ml cell volume.
- Cell volume is determined by pelletting the cell suspension at 800 xg for 20 minutes. The cells are then resuspended and sonically disrupted. The disrupted suspension is then gently agitated for a minimum of 1 hour at 4°C. The suspension is then clarified by low speed centrifugation followed by centrifugation at 100,000 xg for 90 minutes.
- the clear middle layer is harvested and used as crude antigen.
- the upper cloudy layer is first treated with freon to remove lipids and also used as crude antigen.
- the protein concentration of this preparation usually ranges between 6 and 7 mg/ml.
- Glycosylated viral antigens which include antigens R 2 and R 3 are extracted from crude antigen with lentil bean lectin.
- the lectin is commercially supplied conjugated to agarose beads (E-Y Laboratories, 127 N. Amphledt Blvd., San Mateo, CA 94401). Equal, volumes of agarose-lectin and the combined crude antigen are mixed together and permitted to react overnight at 4°C. The preparation is then washed to remove non-absorbed antigen. The washed lectin-agarose is then treated with a 2% solution of ⁇ -methyl mannopyranoside to elute the glycosylated viral proteins.
- the porcine immunoglobulins specific for the PR virus glycosylated proteins R 2 and R 3 were reacted with commercially supplied formalinized Staph. aur. (Cowan strain 1) obtained from Bethesda Research Laboratories, Inc.
- the immunoglobulin (6 mg/ml) was added to a 10% suspension of the Staph. aur. in 0.1 M phosphate-buffered saline pH 7.2 at the rate of 0.1 ml immunoglobulin to 1.0 ml of bacterial suspension. The mixture was gently agitated at 4°C overnight.
- the immunoglobulin-coated bacterial cells were washed free of non-attached immunoglobulin and mixed with a lectin purified preparation of PR virus antigens containing the glycosylated immunogens R 2 and R 3 .
- the Staph. aur. suspension was then washed to remove the unbound PR viral antigens.
- the resulting preparation was then used with or without adjuvant as a vaccine for pseudorabies in pigs.
- VAC Freund's incomplete adjuvant
- VAC vaccine without adjuvant
- Both vaccine groups received a second inoculation 3 weeks after the first and were subsequently challenged 3 weeks later by nasally administering 10 8.7 PFU of virulent PR virus.
- the effectiveness of the vaccine was demonstrated by monitoring the anamnestic antibody response of the vaccinates, and the virus secretion patterns and weight gain of control and vaccinated pigs. The data obtained is summarized below in
- a vaccine for immunizing pigs against pseudorabies was prepared, using the general procedure of Example I, except that the vaccine contained a larger number of antigenic proteins.
- the difference between the vaccine preparations of Examples I and II is that the vaccine of Example II contains the antigens that are selectively bound by lentil bean lectin.
- immunoglobulins that are used to coat the formalinized Protein A - containing Staph aureus were derived from serums of pigs that had been immunized with Lectin PRV vaccine.
- the lectin PRV vaccine is produced as indicated above in Paragraphs 1 and 2 of "Preparation of R 2 and R 3 Antigens" and as further indicated below.
- glycosylated viral antigens as obtained in Example I are extracted from crude antigen with lentil bean lectin.
- the lectin is commercially supplied conjugated to agarose beads. Equal volumes of agarose-lectin and the combined crude antigen are mixed together and permitted to react overnight at 4°C. The preparation is then washed to remove non-adsorbed antigen. This preparation is then mixed 1:1 with Freund's incomplete adjuvant and used as vaccine.
- a bovine herpesvirus-1 (IBR) vaccine (Lupton and Reed, Patent No. 4,291,019) is purified further by use of the Protein A separator complex.
- Antibody used in this procedure is monospecific for the immunizing protein (s) of the virus and is prepared by conventional protein purification methods or by the monoclonal antibody technology. The higher purity of an IBR vaccine processed through the separator complex will allow easy development of diagnostic serologic tests, which can be used to differentiate naturally infected cattle from vaccinated cattle.
- the immunizing proteins of Brucella are identified, and monospecific antibody against the immunizing protein (s) are prepared and used in the separator complex. This will allow easy production of a purified subunit vaccine for Brucella
- the current whooping-cough vaccine for humans contains inactivated whole B. pertussis organisms. This vaccine causes some local toxic reaction and occasional cases of allergic encephalitis.
- An extract vaccine has been proposed to circumvent these undesirable side-effects. See Swick, et al., New Developments with Human and Veterinary Vaccines, 143-155 (1980, Alan R. Liss, Inc.).
- the separator complex of this invention can be used against the immunizing fraction of B. pertussis. This will yield rapid purification of the immunogen and, more importantly, separation of the immunogen from the allergenic and toxogenic fractions. Simi larly, the separator complex can be used for preparation of vaccines for foot and mouth disease (FMD) of cattle. In FMD there are allergic reactions caused by media components (horse serum) and cell components (baby hamster kidney cell cultures) which are reported to cause anaphylactic reactions in vaccinated cattle. These undesirable components can be eliminated from the vaccines.
- FMD foot and mouth disease
- the method of this invention can also be used to extract specific protective antigens from protozoans such as Babesia bovis, a cattle pathogen.
- a separator complex is prepared containing conventional immunoglobulins or monoclonal antibody specific for protective antigens.
- Babesia bovis-infected red blood cells are then produced by infecting splenectomized cattle with the pathogen or by propagating the protozoan in vitro (Erp et al., 1978; Am. J. Trop. Med. Hyg. 27, 1062-1064).
- the infected red blood cells are separated from serum and/or culture components, washed, and solubilized by sonification and/or treatment by non-ionic detergents such as Triton-X-100.
- the separator complex is then added to the solubilized preparation as described in example I and the specific antigen (s) is (are) removed.
- the recovered antigen (s) that are bound to the separator complex are then washed to remove un
- Specific protective solubilized viral antigen can also be retrieved by separator complexes that do not consist of Staph A.
- An example of such a separator complex is Protein A covalently linked to Sepharose CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ) and to which has been bound an immunoglobulin of particular antigen specificity.
- the separator complex is then used to selectively remove specific antigens from solubilized crude virus antigen preparations by the batch technique as described in Example I.
- the separator complex containing antigen is washed to remove unbound PR viral antigens and the resulting preparation is used with or without adjuvant as a vaccine for pseudorabies in pigs.
- Micro-particles containing immobilized protein A are prepared from serum albumin and pure Protein A.
- the albumin employed is preferably a serum albumin of the species of animal to which the vaccine is to be administered, such as swine albumin for a swine vaccine, etc.
- the Protein A may be obtained from Pharmacia Fine Chemicals, Piscataway, New Jersey. A modification of published procedures may be used, as described in United States Patent 4,230,685, and/ or Scheffel, et al, J. Nuclear Med. , Vol. 13, No. 7, 498-503 (1972).
- the serum albumin may be dissolved in distilled water to an albumin concentration of about 20-25%, viz., 250 milligrams (mg) per milliliter (ml) of water give a 20% solution.
- the water-soluble Protein A Into this aqueous albumin solution there is added the water-soluble Protein A in an amount of about 50-60 milligrams (mg) per milliliter (ml) of solution.
- This aqueous mixture is then dispersed in a vegetable oil, such as cottonseed oil, to form a fine water-in-oil emulsion.
- 1.0 parts of the aqueous solution may be dispersed in 120 parts of vegetable oil, and the emulsion homogenized by sonication. The homogenate is added dropwise.
- the resulting washed microspheres provide surfaces containing Protein A, and therefore can be used to prepare vaccines according to the foregoing examples, as the substitute for the S . aureus cells or the Protein A Sepharose column beads.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Purified antigenically selective vaccines for domestic animals are prepared from microorganism cultures containing the immunizing agent by first complexing the immunizing agent with micro-particles having bound IgG antibodies specific for the immunizing agent, separating the resulting complex, and preparing a vaccine directly therefrom containing the antigen-antibody complex. The micro-particles preferably have Protein A in their outer surfaces for binding to the specific antibodies. The complex-containing vaccines provide effective immunization. The method and the resulting vaccines are particularly useful in preparing viral and bacterial subunit vaccines.
Description
PURIFIED AND ANTIGENICALLY SELECTIVE VACCINES FOR DOMESTIC ANIMALS
Field and Objectives of Invention
The field of this invention is animal vaccines prepared from aqueous microorganism cultures. The desired immunizing agent which has been propagated by a culture procedure may be a virus, a bacteria, or other microorganism such as a protozoa. The method is highly advantageous for preparing vaccines from soluble protein or glycoprotein antigens derived from virus or bacteria.
The objectives of this invention involve the recovery of the selected immunizing agent in purified form, and its incorporation in a parenteral vaccine of effective immunogenicity. More specifically, it is an objective to provide a method in which the specific immunizing agent can be recovered and incorporated in substantially pure form in a vaccine while at the same time reducing the required number of preparatoy steps, and thereby reducing the cost of the preparation of the vaccine. These objectives are particularly important with respect to subunit viral and bacterial vaccines of practical and commercial use of which has been limited by the high cost of preparation. In the preparation of vaccine from bacterial cells, the cells can be readily separated from the culture media suspensions by centrifigation, and after separation, they can be washed to remove soluble residues. Solubilized bacterial antigens, viruses, andsubunit viral proteins are much more difficult to prepare as purified concentrates.
Viruses for vaccine use are produced in cell-containing media, adapted tissue cells or other cells serving as the host for the propagation of the virus. The cells can be
lysed to liberate the virus, but it is difficult to efficiently separate the viral particles for the other solids of the media residues. Such separation is even more difficult where the viral protein has been solubilized, such as by the action of a nonionic detergent, the antigenic proteins being in solution together with other soluble substances. Similar problems are encountered when antigenic components of bacteria are solublized, or where the desired antigen is produced in soluble form by a genetic engineering procedure, such as the culturing of cells containing plasmids providing genetic units producing the desired antigenic protein.
There has been a recognized need for better methods of recovering and concentrating the immunizing agents used in animal vaccines. This need has been particularly evident with respect to non-cellular immunizing agents such as virus, and solubilized antigenic protein derived from virus or bacteria.
SUMMARY OF INVENTION
It is known that IgG antibodies that bind selectively to specific antigenic protein can be prepared and used for the separation of the antigenic protein. For this purpose. Protein A has been used as a surface-component of the micro-particles to be employed for the separation. For example, Protein A may be coupled to beads of a chromatographic adsorbent such as cross-linked agarose gel beads. The Protein A binds with the Fc regions of the specific antibodies, leaving the Fab arms free for binding with the antigenic protein. Heretofore, however, after separation of the virus by adsorption on the antibody coated particles, the antigenic protein is recovered by breaking the complex, such as by the use of a suitable
eluting agent in column adsorption procedures. It is not heretofore been recognized that the antigen-antibody- Protein A-carrier particle complex can be directly used as a vaccine. The method and vaccines of this invention are based in part on the discovery that after adsorption of the antigen further processing is not necessary, and that vaccines providing effective immunization can be directly prepared from the adsorption complex. This is surprising since the immunizing activity of the antigenic protein would have been thought to have been interfered with by the antibody binding.
The method of this invention and the vaccines produced thereby can be applied with particular advantage to the preparation of subunit viral vaccines. This invention provides an efficient way of preparing such vaccines on a commercial basis. This is important because subunit viral vaccines can be used in conjunction with programs for eradication of bacterial and viral diseases. The immunity produced by a subunit vaccine can be distinguished from the immunity of natural infection because a larger complement of antibodies will be present after natural infection.
DETAILED DESCRIPTION
The antibody-binding micro-particles used in preparing vaccines according to the present invention may comprise killed bacterial cells having a protein substance in their cell walls capable of selective binding to the Fc regions of the antibodies. For example, it may be the substance known as Protein A, and the cells providing Protein A in the cells walls may be Staphylococcus aureus. Preserved (e.g. formalinized) cells of S. aureus (Cowan 1 Strain) are available from Calbiochem-Behring Corp., San Diego, California; or from Bethesda Research Laboratories, Inc., Gaithersburg, Maryland. Alternatively, other killed
bacterial cells can be used which have a cell wall protein binding to the Fc regions of the antibodies.
The protein A or other Fc-binding bacterial protein may be immobilized on synthetically prepared micro-particles or microspheres, such as the chromatographic gel beads used in chromatography adsorption columns. Protein A or similar protein may be chemically coupled to the substance forming the microspheres. A commercial product of this kind is available from Pharmacia Fine Chemicals, a division of Pharmacia, Inc., Piscataway, New Jersey, being sold as Protein A-Sepharose CL-4B, which comprises Protein-A covalently coupled to the cross-linked agarose gel beads. Alternatively, microspheres providing Protein A in their outer surfaces can be prepared by mixing the Protein A with aqueous albumin and forming the mixture into microspheres by the hot oil method described in United States Patent 4,230,685, or as described in Scheffel, et al, J. Nuclear Med. , Vol. 13, No. 7, 498-503 (1972). For the purpose of the present invention if the procedure, of Patent 4,230,685 is followed, the magnetic particles will be omitted from the microspheres, the resulting procedure being similar to that described by the cited Scheffel, et al reference.
The antibody preparations useful in the present invention are those which contain one or more specific antibodies having Fb regions reacting with Protein A or similar protein on the surfaces of the micro-particles. For example, Protein A is able to interact with a wide variety of IgG molecules from various species. The antibodies may be prepared in the same species of animals from which the vaccine is to be used, such as cattle, sheep, or swine. A hyperimmune serum can be prepared according to known procedures. See, for example Methods in Immunology and Immunochemistry, I, 209-224 (1967, Academic Press).
Where the specific antibody of the species to be immunized are not reactive with the Protein A, the antibodies can be prepared in another host animal. For example, rabbits can be used since the rabbit immunoglobulins binding to Protein A include all subclasses of IgG. Also, mouse monoclonal antibodies specific for the desired antigen can be employed.
The antibodies can be readily removed from dilute solutions thereof, such as animal sera, by contacting the solutions with the micro-particles. This contacting reaction can be carried out in a column or on a batch basis. The resulting separated complex of the antibody-Protein A-carrier particle is then used to prepare the vaccine, and is hereinafter referred to as the separator complex.
The immunizing agent is prepared by in vitro microorganism culture. Virus may be propagated in cell culture in an aqueous medium, and the virus liberated by rupturing (lysing) cells, such as by sonication. Viral particles are liberated into the aqueous medium, and the residue solids of the cell mass can be separated by centrifigation, leaving the viral particles in the aqueous medium, which will also contain other components such as unwanted antigenic protein and other culture residue substances. For the preparation of a subunit viral vaccine, the virus may be dissolved by addition of a solubilizing agent, such as nonionic detergent, or a proteolytic enzyme. Antigens may also be extracted from the membranes of virus infected cells with non-ionic detergents.
The antibodies immobilized on the micro-particles will be specific to the desired immunizing agent, such as
antibodies which bind to the whole virus, or antibodies which bind to selected antigenic protein constituents of the solubilized virus or extracted antigens. The antigens may be envelope glycoproteins or one or more specific glycoproteins or other protein constituents of the virus.
The method of this invention can also be applied to the preparation of vaccines from specific antigens produced by genetic engineering procedures. The plasmid-containing cells are propagated in aqueous medium to produce the antigen, which may have been at least partly liberated into the aqueous media. Usually, the cells will be lysed to further liberate the soluble antigen, and the cell mass removed to provide an aqueous solution of the antigen which will also contain unwanted antigenic protein and other culture residue substances. This solution is then processed in the same manner as described above for subunit viral protein.
In still another application, the method of this invention may be used for the recovery of protozoan parasites such as Babesia species which occur in red blood cells. These agents can be produced in large quantities by infecting splenectomized animals or by in vitro propagation. Red blood cells containing the agents are first lysed releasing the protozoan. The liberated protozoans and those protozoans that occur extracellularly are then aggregated by specific antibodies adsorbed to protein A immobilized on microparticles or to protein A contained on the surface of Staphylococcus aureus. The aggregated antigen-antibody complexes are separated from the particulate and soluble remnants of red blood cells by differential centrifugation and washing.
The reaction of the immunizing agent in the aqueous admixture with the separator complex may be carried out on a batch basis or in a column. In a batch reaction, the antigenic protein in solution will bind to the separator complex so that the resulting antigenic complex can be readily separated from the residual solution by standard separating procedures such as centrifigation. Where the reaction is carried out in a column, the antigen will be held up by selective adsorption on the separator complex, while a residual solution will pass through and out of the column. The column material containing the adsorbed antigen can then be removed from the column, after washing, if desired, and used to prepare the vaccine in the same manner as the separated precipitate from the batch reaction. Preferably, a sufficient amount of the separator complex is present to react with all of the antigenic protein. If desired, excess separator complex can be present, and such excess separator complex may be separated with the antigenic protein complex, and may remain in the preparation for vaccine use. Preferably, however, any such excess is kept to a minimum to reduce costs in preparing the vaccine.
After recovery, the complexed immunizing agent is prepared in vaccine dose form for administration to the domestic animal. For example, the particulate antigenic complex may be suspended in an injectable liquid carrier, such as a sterile phosphate-buffered saline solution, as used for parenteral injections. Additionally, however, standard adjuvant compositions can be combined with the complexed immunizing agent to enhance the immunogenic response. For example, an aluminum hydroxide adjuvant can be employed, or an oil-type adjuvant such as vegetable oil adjuvant, Freund's Incomplete Adjuvant, etc.
The method of this invention and the vaccines which can be produced thereby are further illustrated by the following examples.
EXAMPLE I
A subunit vaccine for immunizing pigs against Pseudorabies was prepared as follows:
Preparation of R2 and R3 Antigens
1. Pseudorabies virus was progated by cultivation of the virus in a pig kidney cell line. The virus infected cells are harvested when 100% of the cell monolayer shows σytopathic effect.
2. The cells are washed and then extracted with a
1% solution of Triton-X-100 prepared in Tris/Tricine buffer .025 M pH 8.6. The detergent solution is added at the rate of 1 ml per 1 ml cell volume. Cell volume is determined by pelletting the cell suspension at 800 xg for 20 minutes. The cells are then resuspended and sonically disrupted. The disrupted suspension is then gently agitated for a minimum of 1 hour at 4°C. The suspension is then clarified by low speed centrifugation followed by centrifugation at 100,000 xg for 90 minutes. The clear middle layer is harvested and used as crude antigen. The upper cloudy layer is first treated with freon to remove lipids and also used as crude antigen. The protein concentration of this preparation usually ranges between 6 and 7 mg/ml. The two layers were combined.
3. Glycosylated viral antigens which include antigens R2 and R3 are extracted from crude antigen with lentil bean lectin. The lectin is commercially supplied conjugated to agarose beads (E-Y Laboratories, 127 N. Amphledt Blvd., San Mateo, CA 94401). Equal, volumes of agarose-lectin and the combined crude antigen are mixed together and permitted to react overnight at 4°C. The preparation is then washed to remove non-absorbed antigen. The washed lectin-agarose is then treated with a 2% solution of α-methyl mannopyranoside to elute the glycosylated viral proteins.
The porcine immunoglobulins specific for the PR virus glycosylated proteins R2 and R3 were reacted with commercially supplied formalinized Staph. aur. (Cowan strain 1) obtained from Bethesda Research Laboratories, Inc. The immunoglobulin (6 mg/ml) was added to a 10% suspension of the Staph. aur. in 0.1 M phosphate-buffered saline pH 7.2 at the rate of 0.1 ml immunoglobulin to 1.0 ml of bacterial suspension. The mixture was gently agitated at 4°C overnight. The following morning the immunoglobulin-coated bacterial cells were washed free of non-attached immunoglobulin and mixed with a lectin purified preparation of PR virus antigens containing the glycosylated immunogens R2 and R3. The Staph. aur. suspension was then washed to remove the unbound PR viral antigens. The resulting preparation was then used with or without adjuvant as a vaccine for pseudorabies in pigs.
Seven weaning pigs were randomly split into a control group of 3 and 2 vaccine groups of 2 pigs each. The first vaccine group received 1 ml of the above vaccine preparation mixed in an equal volume of Freund's incomplete adjuvant, designated "VAC (FIA) " . The second vaccine group received 1 ml of vaccine without adjuvant, designated "VAC". Both vaccine groups received a second inoculation 3 weeks after the first and were subsequently challenged 3 weeks later by
nasally administering 108.7 PFU of virulent PR virus. The effectiveness of the vaccine was demonstrated by monitoring the anamnestic antibody response of the vaccinates, and the virus secretion patterns and weight gain of control and vaccinated pigs. The data obtained is summarized below in
Tables A and B. The antibody response was determined by the serum neutralization plaque reduction method.
A vaccine for immunizing pigs against pseudorabies was prepared, using the general procedure of Example I, except that the vaccine contained a larger number of antigenic proteins. The difference between the vaccine preparations of Examples I and II is that the vaccine of Example II contains the antigens that are selectively bound by lentil bean lectin.
To accomplish this the immunoglobulins that are used to coat the formalinized Protein A - containing Staph aureus were derived from serums of pigs that had been immunized with Lectin PRV vaccine.
The lectin PRV vaccine is produced as indicated above in Paragraphs 1 and 2 of "Preparation of R2 and R3 Antigens" and as further indicated below.
The glycosylated viral antigens as obtained in Example I are extracted from crude antigen with lentil bean lectin. The lectin is commercially supplied conjugated to agarose beads. Equal volumes of agarose-lectin and the combined crude antigen are mixed together and permitted to react overnight at 4°C. The preparation is then washed to remove non-adsorbed antigen. This preparation is then mixed 1:1 with Freund's incomplete adjuvant and used as vaccine.
A bovine herpesvirus-1 (IBR) vaccine (Lupton and Reed, Patent No. 4,291,019) is purified further by use of the Protein A separator complex. Antibody used in this procedure is monospecific for the immunizing protein (s) of the virus and is prepared by conventional protein purification methods or by the monoclonal antibody technology. The higher purity of an IBR vaccine processed through the separator complex will allow easy development of diagnostic serologic tests, which can be used to differentiate naturally infected cattle from vaccinated cattle.
EXAMPLE IV
The immunizing proteins of Brucella are identified, and monospecific antibody against the immunizing protein (s) are prepared and used in the separator complex. This will allow easy production of a purified subunit vaccine for
Brucella by passing solubilized Brucella organisms over the separator complex. Such a vaccine would allow development of a Brucella diagnostic test utilizing any of the antigens not included in the vaccine. This diagnostic test would be significantly better than the current diagnostic tests in the Brucella control program. In the current test, vaccine response is differentiated from natural exposure (infection) response by multiple serological testing. This has not been satisfactory because of the time required. A control program built around a separator complex purified vaccine would utilize diagnostic tests which would not necessarily be based on multiple serological tests but would be based upon the presence or absence of antibody against the diagnostic antigens.
EXAMPLE V
The current whooping-cough vaccine for humans contains inactivated whole B. pertussis organisms. This vaccine causes some local toxic reaction and occasional cases of allergic encephalitis. An extract vaccine has been proposed to circumvent these undesirable side-effects. See Swick, et al., New Developments with Human and Veterinary Vaccines, 143-155 (1980, Alan R. Liss, Inc.). The separator complex of this invention can be used against the immunizing fraction of B. pertussis. This will yield rapid purification of the immunogen and, more importantly, separation of the immunogen from the allergenic and toxogenic fractions. Simi larly, the separator complex can be used for preparation of vaccines for foot and mouth disease (FMD) of cattle. In FMD there are allergic reactions caused by media components (horse serum) and cell components (baby hamster kidney cell cultures) which are reported to cause anaphylactic reactions in vaccinated cattle. These undesirable components can be eliminated from the vaccines.
EXAMPLE VI
The method of this invention can also be used to extract specific protective antigens from protozoans such as Babesia bovis, a cattle pathogen. To accomplish this a separator complex is prepared containing conventional immunoglobulins or monoclonal antibody specific for protective antigens. Babesia bovis-infected red blood cells are then produced by infecting splenectomized cattle with the pathogen or by propagating the protozoan in vitro (Erp et al., 1978; Am. J. Trop. Med. Hyg. 27, 1062-1064). The infected red blood cells are separated from serum and/or culture components, washed, and solubilized by sonification and/or
treatment by non-ionic detergents such as Triton-X-100. The separator complex is then added to the solubilized preparation as described in example I and the specific antigen (s) is (are) removed. The recovered antigen (s) that are bound to the separator complex are then washed to remove unabsorbed materials and used as vaccine.
EXAMPLE VII
Specific protective solubilized viral antigen can also be retrieved by separator complexes that do not consist of Staph A. An example of such a separator complex is Protein A covalently linked to Sepharose CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ) and to which has been bound an immunoglobulin of particular antigen specificity. The separator complex is then used to selectively remove specific antigens from solubilized crude virus antigen preparations by the batch technique as described in Example I. The separator complex containing antigen is washed to remove unbound PR viral antigens and the resulting preparation is used with or without adjuvant as a vaccine for pseudorabies in pigs.
EXAMPLE VIII
Micro-particles containing immobilized protein A are prepared from serum albumin and pure Protein A. The albumin employed is preferably a serum albumin of the species of animal to which the vaccine is to be administered, such
as swine albumin for a swine vaccine, etc. The Protein A may be obtained from Pharmacia Fine Chemicals, Piscataway, New Jersey. A modification of published procedures may be used, as described in United States Patent 4,230,685, and/ or Scheffel, et al, J. Nuclear Med. , Vol. 13, No. 7, 498-503 (1972). For example, the serum albumin may be dissolved in distilled water to an albumin concentration of about 20-25%, viz., 250 milligrams (mg) per milliliter (ml) of water give a 20% solution. Into this aqueous albumin solution there is added the water-soluble Protein A in an amount of about 50-60 milligrams (mg) per milliliter (ml) of solution. This aqueous mixture is then dispersed in a vegetable oil, such as cottonseed oil, to form a fine water-in-oil emulsion. For example, 1.0 parts of the aqueous solution may be dispersed in 120 parts of vegetable oil, and the emulsion homogenized by sonication. The homogenate is added dropwise. to a constantly stirred bath of vegetable oil, such as cottonseed oil, maintained at a temperature of 120-125°C for 10 to 15 minutes. The resulting microspheres are recovered by centrifigation, and washed to remove the vegetable oil on the surface of the particles, using an oil solvent such as diethyl ether.
The resulting washed microspheres provide surfaces containing Protein A, and therefore can be used to prepare vaccines according to the foregoing examples, as the substitute for the S . aureus cells or the Protein A Sepharose column beads.
Claims
1. The method of preparing a purified antigenically selective vaccine for a domestic animal, comprising:
(a) preparing by in vitro microorganism culture an aqueous admixture of the desired animal disease immunizing agent together with unwanted antigenic protein and culture residue substances;
(b) complexing IgG antibodies specific for the said immunizing agent with micro-particles having outer surfaces containing protein selectively binding to the Fc region of the IgG antibodies so that the antibody Fab regions of the resulting first complex are oriented for binding reaction;
(c) reacting said immunizing agent in said aqueous admixture with said first complex to form a second complex;
(d) recovering said second complex from said aqueous admixture in purified form; and
(e) preparing a parenteral vaccine from said second complex by suspending it in parenterally-injectable liquid carrier for animal vaccines.
2. The method of claim 1 in which said immunizing agent is whole virus.
3. The method of claim 1 in which said immunizing agent is antigenic protein in aqueous solution in said admixture.
4. The method of claim 1 in which said immunizing agent is pseudorabies virus.
5. The method of claim 1 in which said immunizing agent is viral antigenic glycoprotein in aqueous solution in said admixture.
6. The method of claims 1 to 5 in which said liquid vaccine carrier contains an immunization-promoting adjuvant.
7. The vaccines produced by the methods of claims 1 to 5.
8. The vaccines of claim 7 which also contain an immunization-promoting adjuvant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21291/83A AU2129183A (en) | 1982-10-05 | 1983-09-23 | Purified and antigenically selective vaccines for domestic animals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/432,967 US4493825A (en) | 1982-10-05 | 1982-10-05 | Purified and antigenically selective vaccines for domestic animals |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1984001289A1 true WO1984001289A1 (en) | 1984-04-12 |
Family
ID=23718298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1983/001456 WO1984001289A1 (en) | 1982-10-05 | 1983-09-23 | Purified and antigenically selective vaccines for domestic animals |
Country Status (4)
Country | Link |
---|---|
US (1) | US4493825A (en) |
EP (1) | EP0120955A4 (en) |
CA (1) | CA1213828A (en) |
WO (1) | WO1984001289A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562147A (en) * | 1983-06-13 | 1985-12-31 | Regents Of The University Of Minnesota | Method and kit for diagnosis of pseudorabies |
WO2019199918A1 (en) * | 2018-04-11 | 2019-10-17 | Cowan Fred M | Compositions and methods for prevention and treatment of immune complex disease |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683137A (en) * | 1982-04-16 | 1987-07-28 | Cornell Research Foundation, Inc. | Temperature sensitive reassortant viruses and a vaccine against equine influenza |
US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
US4981685A (en) * | 1986-03-07 | 1991-01-01 | Utah State University Foundation | Bacterial extract vaccines for veterinary application |
BR9007702A (en) * | 1989-10-02 | 1992-08-18 | Embrex Inc | TREATMENT METHOD |
JP3078013B2 (en) * | 1989-10-02 | 2000-08-21 | エンブレックス インコーポレイテッド | Uses of vaccine conjugates, vaccine preparations and articles of manufacture |
US5397568A (en) * | 1989-10-02 | 1995-03-14 | Whitfill; Craig E. | Method of treating infectious bursal disease virus infections |
US5549899A (en) * | 1992-12-04 | 1996-08-27 | University Technologies International, Inc. | Giardia vaccine |
US5512288A (en) * | 1992-12-04 | 1996-04-30 | University Technologies International, Inc. | Giardia vaccine |
DE19531226C1 (en) * | 1995-08-24 | 1997-04-03 | Immuno Ag | Pharmaceutical compsn. for prevention or treatment of viral disease |
PT1292327E (en) * | 2000-06-12 | 2007-05-31 | Univ Saskatchewan | Immunization of dairy cattle with mig protein |
AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
US20080311135A1 (en) * | 2007-05-22 | 2008-12-18 | Baylor College Of Medicine | Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations |
CN103140500B (en) | 2010-07-14 | 2015-09-09 | 默沙东公司 | Anti-addl monoclonal antibody and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189466A (en) * | 1975-09-19 | 1980-02-19 | Technical Research Affiliates, Inc. | Detection of rheumatoid factor by antibody sensitized microbial particles |
US4230685A (en) * | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
FR2356428A1 (en) * | 1976-06-29 | 1978-01-27 | Inserm Ctre Technologie Biomed | PROCESS FOR PREPARATION OF AN IMMUNOLOGICAL ANTIPARASITIC AGENT, PRODUCT OBTAINED AND ITS APPLICATION |
FR2403081A1 (en) * | 1977-09-19 | 1979-04-13 | Merieux Inst | NEW PARTICULAR MATERIAL, ITS PREPARATION AND APPLICATION, ESPECIALLY AS A MEDICINAL PRODUCT |
DE2836046A1 (en) * | 1978-08-17 | 1980-02-28 | Behringwerke Ag | IMMUNOLOGICAL DETERMINATION PROCEDURE |
-
1982
- 1982-10-05 US US06/432,967 patent/US4493825A/en not_active Expired - Fee Related
-
1983
- 1983-09-23 EP EP19830903630 patent/EP0120955A4/en not_active Withdrawn
- 1983-09-23 WO PCT/US1983/001456 patent/WO1984001289A1/en not_active Application Discontinuation
- 1983-09-26 CA CA000437580A patent/CA1213828A/en not_active Expired
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189466A (en) * | 1975-09-19 | 1980-02-19 | Technical Research Affiliates, Inc. | Detection of rheumatoid factor by antibody sensitized microbial particles |
US4230685A (en) * | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562147A (en) * | 1983-06-13 | 1985-12-31 | Regents Of The University Of Minnesota | Method and kit for diagnosis of pseudorabies |
WO2019199918A1 (en) * | 2018-04-11 | 2019-10-17 | Cowan Fred M | Compositions and methods for prevention and treatment of immune complex disease |
Also Published As
Publication number | Publication date |
---|---|
EP0120955A4 (en) | 1986-11-04 |
EP0120955A1 (en) | 1984-10-10 |
CA1213828A (en) | 1986-11-12 |
US4493825A (en) | 1985-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4493825A (en) | Purified and antigenically selective vaccines for domestic animals | |
US4816253A (en) | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
WO1982000205A1 (en) | Non-a,non-b hepatitis assay and vaccine | |
JPH07508498A (en) | Staphylococcus epidermidis-associated type I and II surface antigens | |
US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
CA1168579A (en) | Non-a, non-b hepatitis virus | |
EP0431023B1 (en) | Gamma inulin compositions | |
US4845042A (en) | Adjuvant for immunization | |
EP0120922B1 (en) | Lectin-containing anti-viral vaccines for domestic animals and method of preparation | |
JPH0764753B2 (en) | Preparation of high-purity gammaglobulin without hepatitis-B-virus infectivity | |
Schmidt et al. | Immunodiffusion reactions with rubella antigens | |
US4572834A (en) | Biologic and method of preparing same | |
EP0101505B1 (en) | Method for the purification of parasite antigenic factors | |
Singh et al. | Blood plasma from survivors of COVID-19: a novel and next frontier approach to fight against pandemic coronavirus | |
US6646108B1 (en) | Process for isolating IgG and IgA | |
Kjeilén | Reactions between adenovirus antigens and papain digested rabbit immune globulin | |
KR100290059B1 (en) | How to Extract Cell-Binding Proteins from Bordetella | |
Vaheri et al. | Small size rubella virus antigens and soluble immune complexes: analysis by the platelet aggregation technique | |
US4687665A (en) | Biologic and method of preparing same | |
Frommhagen et al. | A comparison of fluorescein-labeled γ-globulins purified by Rivanol and DEAE chromatography | |
JP2004524369A (en) | Method for producing vaccine | |
JP4735954B2 (en) | Antibody production carrier | |
RU2304587C2 (en) | METHOD FOR SELECTIVE ISOLATION OF IgV ANTIBODIES FROM ANSERES ORDER BIRD EGG YOLK (VARIANTS) | |
JPH07116057B2 (en) | Immune enhancer and enhancing antigen | |
EP0282965A2 (en) | Treponema hyodysenteriae antigen and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Designated state(s): AT CH DE FR GB NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1983903630 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1983903630 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1983903630 Country of ref document: EP |